Bank of America
ELVN icon

Bank of America’s Enliven Therapeutics ELVN Stock Holding History

Bank of America’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97M Buy
98,023
+52,861
+117% +$2.24M ﹤0.01% 3569
2026
Q1 		$1.77M Buy
45,162
+12,451
+38% +$345K ﹤0.01% 4192
2025
Q4 		$504K Buy
32,711
+9,168
+39% +$183K ﹤0.01% 4911
2025
Q3 		$482K Sell
23,543
-965
-4% -$19.5K ﹤0.01% 5811
2025
Q2 		$492K Buy
24,508
+4,078
+20% +$77.2K ﹤0.01% 5721
2025
Q1 		$402K Sell
20,430
-13,757
-40% -$296K ﹤0.01% 5772
2024
Q4 		$769K Sell
34,187
-14,504
-30% -$376K ﹤0.01% 5247
2024
Q3 		$1.24M Buy
48,691
+14,459
+42% +$335K ﹤0.01% 4910
2024
Q2 		$800K Buy
34,232
+17,494
+105% +$368K ﹤0.01% 5038
2024
Q1 		$294K Sell
16,738
-13,989
-46% -$215K ﹤0.01% 5669
2023
Q4 		$425K Buy
30,727
+7,621
+33% +$93.2K ﹤0.01% 5607
2023
Q3 		$316K Buy
23,106
+6,063
+36% +$102K ﹤0.01% 5631
2023
Q2 		$348K Buy
17,043
+10,498
+160% +$212K ﹤0.01% 5499
2023
Q1 		$143K Buy
6,545
+6,487
+11,184% +$132K ﹤0.01% 6100
2022
Q4 		$940 Buy
+58
New +$927 ﹤0.01% 7354
2022
Q1 		– Sell
-2,370
Closed -$21K – 8382
2021
Q4 		$21K Buy
2,370
+30
+1% +$393 ﹤0.01% 7501
2021
Q3 		$38K Sell
2,340
-1,570
-40% -$32.6K ﹤0.01% 7165
2021
Q2 		$124K Sell
3,910
-7,837
-67% -$243K ﹤0.01% 6396
2021
Q1 		$396K Buy
11,747
+11,189
+2,005% +$569K ﹤0.01% 5545
2020
Q4 		$49K Buy
558
+241
+76% +$20.2K ﹤0.01% 6333
2020
Q3 		$26K Sell
317
-1,881
-86% -$170K ﹤0.01% 6224
2020
Q2 		$243K Buy
2,198
+1,946
+772% +$218K ﹤0.01% 5104
2020
Q1 		$16K Buy
+252
New +$16.1K ﹤0.01% 6238

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Bank of America's ELVN Position: Q2 2026 in Review

Bank of America increased its Enliven Therapeutics (ELVN) stake by 117% in Q2 2026, buying an estimated $2.24M and bringing the position to 98,023 shares worth $4.97M. The position accounts for ﹤0.01% of the portfolio, ranked #3569.

Bank of America first reported a position in ELVN in Q1 2020 and has held it in 23 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Bank of America held 98,023 shares of Enliven Therapeutics worth $4.97M as of Q2 2026.
  • Bank of America bought 52,861 Enliven Therapeutics shares in Q2 2026, an estimated $2.24M.
  • Enliven Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #3569 holding.
  • Bank of America first reported a position in Enliven Therapeutics in Q1 2020 and has held it in 23 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.